Consequently, pharmacological inhibition or antibody-based targeting of Nuc/AdsA in combination with appropriate antibiotic treatment might become a suitable strategy to improve clinical outcomes of animal or human infections caused by MRSP and related pathogenic staphylococci that exploit the toxigenic properties of dAdo. The gene discussed is RNF170; the disease is infection.